MedPath
HSA Approval

AXCEL CINNARIZINE TABLETS 25 mg

SIN10935P

AXCEL CINNARIZINE TABLETS 25 mg

AXCEL CINNARIZINE TABLETS 25 mg

May 17, 1999

KOTRA PHARMA MARKETING

KOTRA PHARMA MARKETING

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantKOTRA PHARMA MARKETING
Licence HolderKOTRA PHARMA MARKETING

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

N07CA02

cinnarizine

Manufacturer Information

KOTRA PHARMA MARKETING

KOTRA PHARMA (M) SDN BHD

Active Ingredients

CINNARIZINE

25 mg

Cinnarizine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

AXCEL CINNARIZINE TABLETS 25 mg - HSA Approval | MedPath